Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc. (XTNT) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · XTNT · as of Sep 30, 2025
Ownership Breakdown
29
Institutional Holders
$51.96M
Total Inst. Value
▼ $7.13M vs Q2
140.26M
Shares Outstanding
freeFloat 84.01%
80.06M
13F Shares Held
▲ 101,444 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
XTNT largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
NANTAHALA CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 68.39M | 49.09% | 49.09% | $44.38B | Nov 14, 2025 | — held |
AWM INVESTMENT COMPANY, INC. biological products, (no diagnostic substances) | 6.59M | 4.73% | 4.73% | $4.28B | Nov 13, 2025 | ▼ 2.5K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.36M | 1.69% | 1.69% | $1.53B | Nov 7, 2025 | ▲ 104.2K |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 713.9K | 51.25% | 51.25% | $463.26M | Nov 13, 2025 | ▲ 63.2K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 491.9K | 35.31% | 35.31% | $319.31M | Nov 12, 2025 | ▼ 61.7K |
CRESCENT GROVE ADVISORS, LLC biological products, (no diagnostic substances) | 412.0K | 29.58% | 29.58% | $267.36M | Nov 13, 2025 | — held |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 242.9K | 17.44% | 17.44% | $157.63M | Nov 14, 2025 | ▼ 19.6K |
BRIDGEWAY CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 164.1K | 11.78% | 11.78% | $106.48M | Nov 14, 2025 | — held |
PRIVATE ADVISOR GROUP, LLC biological products, (no diagnostic substances) | 123.0K | 8.83% | 8.83% | $79.81M | Nov 13, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 120.3K | 8.64% | 8.64% | $78.08M | Nov 12, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
7
Increased
+202.9K shares4
New Positions
first time holders6
Decreased
−86.1K shares4
Sold Out
fully exitedNet shares change (top 50)
+116.8K
+202.9K / −86.1K
Net new holders
+1
4 new / 4 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
XTNT insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
1
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Schallenberger Mark A. Chief Operating Officer | Feb 15, 2026 | Tax Withhold | 7,709 | $0.58 | $4.5K | 663.2K | Form 4 ↗ |
Neils Scott C CFO and Assistant Secretary | Jan 15, 2026 | Tax Withhold | 8,084 | $0.65 | $5.3K | 843.4K | Form 4 ↗ |
BAKEWELL JOHN K director | Nov 15, 2025 | Award | 158,228 | — | — | 914.1K | Form 4 ↗ |
Vizirgianakis Stavros G. director | Nov 15, 2025 | Award | 553,797 | — | — | 7.52M | Form 4 ↗ |
Beeson Jonn R. director | Nov 15, 2025 | Award | 158,228 | — | — | 517.6K | Form 4 ↗ |
BAKEWELL JOHN K director | Nov 15, 2025 | Award | 158,228 | — | — | 158.2K | Form 4 ↗ |
JAIN ABHINAV director | Nov 15, 2025 | Award | 158,228 | — | — | 158.2K | Form 4 ↗ |
Lipschultz Tyler director | Nov 15, 2025 | Award | 158,228 | — | — | 158.2K | Form 4 ↗ |
Browne Sean E President and CEO | Nov 15, 2025 | Award | 394,937 | — | — | 2.58M | Form 4 ↗ |
Browne Sean E President and CEO | Nov 15, 2025 | Award | 789,874 | — | — | 789.9K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Xtant Medical Holdings, Inc. (XTNT) is primarily owned by institutional investors, who hold approximately 57.1% of total shares outstanding. Company insiders own approximately 15.99%, while retail and public investors account for the remaining 26.93%.
The largest institutional shareholder of Xtant Medical Holdings, Inc. is NANTAHALA CAPITAL MANAGEMENT, LLC, holding approximately 68.39 million shares — equal to 49.09% of outstanding shares — as of September 30, 2025.
A total of 29 institutional investors currently hold XTNT stock, with a combined institutional value of approximately $51,958,021 as of the most recent 13F filing period.
Frequently asked questions
XTNT ownershipXtant Medical Holdings, Inc. (XTNT) is primarily owned by institutional investors, who hold approximately 57.1% of shares. The largest shareholder is NANTAHALA CAPITAL MANAGEMENT, LLC with a 49.09% stake. Company insiders hold 15.99%. Data sourced from SEC Form 13F as of September 30, 2025.